We have observed
2 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after March 23, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Polymorph of Rilpivirine hydrochloride and its use as antiviral
Novel crystalline form of rilpivirine hydrochloride